Product news

Share this article:
Stiefel Laboratories announced that the FDA has approved its new drug application for Extina (ketoconazole) foam, 2% for the treatment of seborrheic dermatitis. The approval, which the company received June 12, clears the way for the product to be sold and marketed in the US.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters